Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Gastroenterology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0016-5085(92)91790-BPMID 1727744
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Double-blind Comparative Study of Omeprazole, 40 mg Once Daily vs Cimetidine, 400 mg q.d.s., in the Treatment of Erosive Reflux Oesophagitis

  1989cited by this paper
• [Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux. Results of a double-blind randomized multicenter trial in France and Belgium].

  1989cited by this paper
• Oméprazole (20 mg/j) comparé à ranitidine (150 mg 2 fois/j) dans le traitement de l'oesophagite par reflux. Résultats d'un essai multicentrique franco-belge, randomisé en double insu.

  1989cited by this paper
• Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study.

  1988cited by this paper
• Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial

  1988cited by this paper
• Healing and relapse of severe peptic esophagitis after treatment with omeprazole.

  1988cited by this paper
• Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis

  1988cited by this paper
• Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial.

  1987cited by this paper
• Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

  1987cited by this paper
• Gastric distention: a mechanism for postprandial gastroesophageal reflux.

  1985cited by this paper
• Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.

  1984cited by this paper
• Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease.

  1984cited by this paper
• Why do apparently healthy people use antacid tablets?

  1983cited by this paper
• Effect of daily oral omeprazole on 24 hour intragastric acidity.

  1983cited by this paper
• Mechanisms of gastroesophageal reflux in patients with reflux esophagitis.

  1982cited by this paper
• Motility of the Digestive Tract

  1982cited by this paper
• Gastric emptying in patients with gastroesophageal reflux.

  1981cited by this paper
• Acid clearance during sleep in the pathogenesis of reflux esophagitis

  1981cited by this paper
• Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects.

  1980cited by this paper
• Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

  1977cited by this paper
• Patterns of Gastroesophageal Reflux in Health and Disease

  1976cited by this paper
• Symptomatic gastroesophageal reflux: Incidence and precipitating factors

  1976cited by this paper
• Effect of bile salts on the ionic permeability of the esophageal mucosa and their role in the production of esophagitis.

  1975cited by this paper
• Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux.

  1974cited by this paper
• Oesophageal acid clearing: One factor in the production of reflux oesophagitis

  1974cited by this paper
• Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux.

  1974cited by this paper
• Role of acid and pepsin in acute experimental esophagitis.

  1969cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Subacute erosive ("peptic") esophagitis associated with achlorhydria.

  1960cited by this paper
• Statistical aspects of the analysis of data from retrospective studies of disease.

  1959cited by this paper
• Role of Bile and Pancreatic Juice in Production of Esophageal Erosions and Anemia.∗

  1951cited by this paper
• Two Cases of Rusty Nail Tetanus, with Tetanus Bacilli in the Inguinal Glands

  1909cited by this paper

• Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials.

  2026cites this paper
• A Comprehensive Review on Omeprazole: Pharmacological Effects and Its Adverse Effects

  2025cites this paper
• Drug treatment strategies for erosive esophagitis in adults: a narrative review

  2025cites this paper
• Proton-Pump Inhibitors in Eosinophilic Esophagitis: A Review Focused on the Role of Pharmacogenetics

  2024cites this paper
• Comparing the efficacy of different proton pump inhibitor dosing regimens for the treatment of gastroesophageal reflux disease: a systematic review and meta-analysis.

  2024cites this paper
• Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis

  2024cites this paper
• Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study

  2023influential citation
• Induction and maintenance of healing in erosive esophagitis in the United States

  2022influential citation
• The Discrepancy Between Subjective and Objective Clinical Endpoints in Gastroesophageal Reflux Disease

  2022cites this paper
• Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis

  2022cites this paper
• Vonoprazan versus proton‐pump inhibitors for healing gastroesophageal reflux disease: A systematic review

  2019cites this paper
• The Oesophagus and Oesophageal Disorders

  2017cites this paper
• The management of gastro-oesophageal reflux disease in the UK Armed Forces

  2017cites this paper
• Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis

  2017cites this paper
• Response to Savarino et al.

  2016cites this paper
• Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?

  2016cites this paper
• Hepatocellular Carcinoma With Peliosis-Like Change-Mimicking Hemangioma: A LI-RADS Exception

  2016cites this paper
• Dyspepsia and Gastro-Oesophageal Reflux Disease: Investigation and Management of Dyspepsia, Symptoms Suggestive of Gastro-Oesophageal Reflux Disease, or Both

  2014cites this paper
• Oesophageal mucosal integrity in non-erosive reflux disease and refractory GORD

  2013cites this paper
• Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial

  2012cites this paper
• Medical Management of Gastroesophageal Reflux Disease

  2012cites this paper
• Gastroesophageal Reflux in Patients Poorly Responsive to Proton Pump Inhibitor Rossetti Fundoplication Is a Safe and Effective Treatment for Both Acid and − Laparoscopic Nissen

  2011cites this paper
• Laparoscopic Nissen–Rossetti Fundoplication Is a Safe and Effective Treatment for Both Acid and Bile Gastroesophageal Reflux in Patients Poorly Responsive to Proton Pump Inhibitor

  2011cites this paper
• Yield of Combined Impedance-pH Monitoring for Refractory Reflux Symptoms in Clinical Practice

  2011cites this paper
• WITHDRAWN: Medical treatments in the short term management of reflux oesophagitis.

  2011cites this paper
• Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease

  2011cites this paper
• An algorithm for diagnosis and treatment of refractory GERD.

  2010cites this paper
• Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis

  2010cites this paper
• The refluxate: The impact of its magnitude, composition and distribution.

  2010cites this paper
• A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis

  2010cites this paper
• Gastro-oesophageal reflux disease.

  2010cites this paper
• Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors

  2010cites this paper
• Disease progression in non-erosive reflux disease (NERD): impact of initial esophageal acid exposure.

  2010cites this paper
• The acid pocket, hiatal hernia and TLESRs : essential players in the pathogenesis of gastro-esophageal reflux disease

  2009cites this paper
• Management of heartburn not responding to proton pump inhibitors

  2009cites this paper
• Essays on health capital and the efficiency of health care

  2009cites this paper
• Systematic review: standard‐ and double‐dose proton pump inhibitors for the healing of severe erosive oesophagitis – a mixed treatment comparison of randomized controlled trials

  2009cites this paper
• CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole

  2009cites this paper
• Prevalence of Complicated Gastroesophageal Reflux Disease and Barrett’s Esophagus Among Racial Groups in a Multi-Center Consortium

  2009cites this paper
• The GABAB receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study

  2009cites this paper
• Diagnostic options for patients with refractory GERD

  2008cites this paper
• A Second-Order Simulation Model of the Cost-Effectiveness of Managing Dyspepsia in the United States

  2008cites this paper
• Comparing Resource Utilization and Gastrointestinal Outcomes in Patients Treated with Either Standard-Dose or High-Dose Proton Pump Inhibitors: A Matched Cohort Study

  2008cites this paper
• Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.

  2008cites this paper
• Yield of 24-Hour Esophageal pH and Bilitec Monitoring in Patients with Persisting Symptoms on PPI Therapy

  2008cites this paper
• Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials.

  2008cites this paper
• MEDICAL TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE

  2008cites this paper
• Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population

  2008cites this paper
• Complete Remission in GERD: Dream or Reality?

  2007cites this paper
• Medical treatments in the short term management of reflux oesophagitis.

  2007cites this paper
• Non-Erosive Reflux Disease (NERD) and Functional Heartburn

  2006cites this paper
• The EAES Clinical Practice Guidelines on Laparoscopic Antireflux Surgery for Gastroesophagel Reflux Disease (1997)

  2006cites this paper
• Long-term experience of treating 185 patients with gastroesophageal reflux disease (GERD) by anti-reflux surgery respecting the functional–morphological restoration of the esophagus

  2006cites this paper
• Comparison of Transesophageal Endoscopic Plication (TEP) with Laparoscopic Nissen Fundoplication (LNF) in the Treatment of Uncomplicated Reflux Disease

  2006cites this paper
• Community-acquired pneumonia and acid-suppressive drugs: position statement.

  2006cites this paper
• Water load test before and after PPI therapy in patients with gastro-oesophageal reflux disease.

  2006cites this paper
• Gastro-oesophageal reflux disease.

  2006cites this paper
• A Multicenter, Randomized, Double-Blind, 8-Week Comparative Trial of Low-Dose Esomeprazole (20 mg) and Standard-Dose Omeprazole (20 mg) in Patients with Erosive Esophagitis

  2006cites this paper
• A Multicenter, Randomized, Double-Blind, 8-Week Comparative Trial of Standard Doses of Esomeprazole (40 mg) and Omeprazole (20 mg) for the Treatment of Erosive Esophagitis

  2006cites this paper
• Treatment of Oesophageal Bile Reflux in Children: The Results of a Prospective Study with Omeprazole

  2006cites this paper
• Summary of Literature Review : Criteria for Use of High-dose Oral Proton Pump Inhibitors

  2005cites this paper
• Title Hepatic tight junctions : From viral entry to cancer metastasis

  2005cites this paper
• Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

  2005cites this paper
• Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A

  2005cites this paper
• Cost-effectiveness of a ‘score and scope’ strategy for the management of dyspepsia

  2005cites this paper
• The Esophageal Cascade : Reflux , Inflammation , Metaplasia , , , , Dysplasia , and Neoplasia

  2005cites this paper
• Treatment of Gastroesophageal Reflux Disease*

  2005cites this paper
• Comparison of Prilosec OTCTM (omeprazole magnesium 20·6 mg) to placebo for 14 days in the treatment of frequent heartburn

  2005cites this paper
• Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials.

  2005cites this paper
• Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis

  2005cites this paper
• Gastroesophageal Reflux Disease Poorly Responsive to Single-Dose Proton Pump Inhibitors in Patients without Barrett's Esophagus: Acid Reflux, Bile Reflux, or Both?

  2004cites this paper
• Single-Isomer Drugs

  2004cites this paper
• Review article: diagnosis and management of night‐time reflux

  2004cites this paper
• Review article: trials on reflux disease — the role of acid secretion and inhibition

  2004cites this paper
• Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities?

  2004cites this paper
• Nocturnal Gastroesophageal Reflux Disease

  2004cites this paper
• A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials

  2004cites this paper
• Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease

  2003cites this paper
• Systematic review : direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease

  2003cites this paper
• Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro‐oesophageal reflux disease and peptic ulcer disease

  2003cites this paper
• Profile and assessment of GERD pharmacotherapy.

  2003cites this paper
• Innovations in Gastro-Intestinal Endoscopy: Endoscopic Antireflux Therapies for Gastro-Oesophageal Reflux Disease

  2003cites this paper
• HEALING HORIZONS IN ACID REFLUX DISEASE : THE MANIFESTATIONS AND MEDICAL MANAGEMENT OF GERD

  2003cites this paper
• Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

  2002cites this paper
• Gastroesophageal reflux disease—should we adopt a new conceptual framework?

  2002cites this paper
• Results of surgical treatment for recurrent postoperative gastroesophageal reflux.

  2002cites this paper
• Medical or Surgical Therapy for Erosive Reflux Esophagitis: Cost–Utility Analysis Using a Markov Model

  2002cites this paper
• Cost-effectiveness and cost-utility of long-term management strategies for heartburn.

  2002cites this paper
• Obstacles to answering doctors' questions about patient care with evidence: qualitative study

  2002cites this paper
• A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial

  2002cites this paper
• A randomized, double‐blind, comparative study of standard‐dose rabeprazole and high‐dose omeprazole in gastro‐oesophageal reflux disease

  2002cites this paper
• Gastroesophageal reflux disease revisited.

  2002cites this paper
• Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis

  2002cites this paper
• Resident Utilization of Information Technology: A Randomized Trial of Clinical Question Formation

  2001cites this paper
• Selection of Patients for Laparoscopic Antireflux Surgery

  2001cites this paper
• Quality of life in patients with gastroesophageal reflux disease.

  2001cites this paper
• Resident utilization of information technology

  2001cites this paper
• Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.

  2001cites this paper
• Non-erosive reflux disease: the real problem in gastro-oesophageal reflux disease.

  2001cites this paper
• Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.

  2001cites this paper